All assets

JOHNSON & JOHNSON (JNJ)

equity · NYSE

Last 30 days
28 mentions · 23 episodes
Last 90 days
28 mentions · 23 episodes

Stance shows how speakers talked about the asset, not investment advice. Figures and views are speaker claims; verify them against the original audio and primary sources.

Mentions over time

bullishbearishmixedneutral
2026-08-24
2026-08-31
2026-09-07
2026-09-14
2026-09-21
2026-09-28
2026-10-05
2026-10-12
2026-10-19
2026-10-26
3
2026-11-02
127
2026-11-09
64
2026-11-16
14

Recent mentions

  1. Investor's Edge with Gary Kaltbaum ·

    Tumbling Down [11.16.2026]

    Gary Kaltbaum bullish

    “A Coca-Cola, Procter Gamble Mondele's, Colgate Palm Olive, Johnson and Johnson, Tiva Pharmaceuticals, Altria Group, that's the cigarettes.”

    Listen at 25:40Original audio

  2. Brew Markets ·

    NVIDIA's China Loophole & The Aviation Blame Game

    John Curteau neutral

    “Meanwhile, over at Johnson Johnson, it's just another mega merger Monday.”

    Listen at 16:11Original audio

  3. Felix Nikolas Prehn's Podcast ·

    Felix Nikolas Prehn: Higher For Longer

    Unidentified speaker (speaker_0) neutral

    “things like Johnson Johnson and Philip Morris and all these kind”

    Listen at 20:27Original audio

  4. Daily Stock Picks ·

    What Happened to Steve Cress at Seeking Alpha? | My Next Steps and my Top Stocks

    Unidentified speaker (speaker_3) neutral

    “But you've got Visa, you've got uh United Health, you've got JNJ, you've got Travelers, you've got Merck, you've got Coke, you've got Amgen, and you've got Chevron.”

    Listen at 30:51Original audio

  5. Morning Call ·

    NVIDIA CEO Drama, FAA Ground Stop Fallout and AI Trade Tests

    Morgan Brennan neutral

    “Financial Times, meantime, says Johnson and Johnson could announce a deal”

    Listen at 27:35Original audio

  6. " Your Financial Future" with Nick Colarossi ·

    "Your Financial Future" with Nick Colarossi of NJC Investments 11/14/2026

    Unidentified speaker (speaker_2) bullish

    “Number two on the list of low volatility, high dividend stocks, Johnson Johnson. We talked about that inside the healthcare ETFs. J and J, the symbol, of course, point two is their beta.”

    Listen at 45:39Original audio

  7. Investor's Edge with Gary Kaltbaum ·

    Worsening [11.13.2026]

    Unidentified speaker (speaker_2) bullish

    “Did I mention Johnson Johnson and the Dow? Very good action.”

    Listen at 18:02Original audio

  8. Investor's Edge with Gary Kaltbaum ·

    Worsening [11.13.2026]

    Unidentified speaker (speaker_2) bullish

    “And in that 19, again, you're ready. Johnson Johnson, and Coca-Cola, Procter, and Gamble.”

    Listen at 27:30Original audio

  9. Investor's Edge with Gary Kaltbaum ·

    Worsening [11.13.2026]

    Unidentified speaker (speaker_2) bullish

    “Johnson. Johnson. Oh, by the way, Disney's near a yearly high, though. Way, I think it's still way down from 2015.”

    Listen at 37:14Original audio

  10. WEALTHTRACK ·

    Great Investor Hersh Cohen explains his powerful compounding strategy.

    Unidentified speaker (speaker_3) neutral

    “I've owned companies like Johnson Johnson, 3M, to name a couple that that their dividends have gone up every year for 50 years or so.”

    Listen at 7:10Original audio

  11. CNBC's "Fast Money" ·

    Nvidia Fallout, AI Financing Risk and Apple’s Safe-Haven Surge 11/12/26

    Unidentified speaker (speaker_0) neutral

    “But on the back of that, J and J, Tim's J and J at all-time highs today.”

    Listen at 29:29Original audio

  12. Best Stocks Now with Bill Gunderson ·

    Thursday Nov. 12, 2026

    Unidentified speaker (speaker_1) neutral

    “There is absolutely nothing in it for me to buy NVIDIA versus Microsoft, to buy AMD versus uh Johnson and Johnson.”

    Listen at 25:38Original audio

  13. Mad Money w/ Jim Cramer ·

    Mad Money w/ Jim Cramer 11/11/26

    Unidentified speaker (speaker_1) bullish

    “rather be in Colgate or Johnson”

    Listen at 3:36Original audio

  14. The Simply Investing Dividend Podcast ·

    EP131: What is Yield on Cost (And Why Does It Matter)?

    Unidentified speaker (speaker_0) neutral

    “0.74%. Uh Johnson Johnson is 1.9%.”

    Listen at 22:04Original audio

  15. Best Stocks Now with Bill Gunderson ·

    Wednesday Nov. 11, 2016 - Bill's Comment on NVDA in Barrons. Huge Jump in AI stocks today.

    Bill Gunderson bullish

    “mean there anybody can come up with what Johnson Johnson has. Q Tips, that what's the barrier to entry with Q TIPS or whatever else, whatever the other products are out there”

    Listen at 17:48Original audio

  16. Making Sense ·

    Rebuilding resilience in America’s pharmaceutical supply chain

    Unidentified speaker (speaker_0) neutral

    “Thanks so much again for doing this. I think just to wrap things up, I'd love to ask for advice on behalf of our CEOs and CFOs in healthcare, biopharma and otherwise. I mean from J and J and otherwise, you've navigated the industry through financial crises, patent cliffs, a pandemic you referred to earlier, and obviously a fundamental rethink of globalization.”

    Listen at 13:06Original audio

  17. Investor's Edge with Gary Kaltbaum ·

    Unwind [11.05.2026]

    Unidentified speaker bearish

    “IBM down seven, Johnson Johnson down four.”

    Listen at 23:38Original audio

  18. Ticker Take ·

    6 Biotech Stocks for a Volatile Bull Market

    Unidentified speaker neutral

    “Legend makes a cancer treatment with Johnson Johnson.”

    Listen at 5:10Original audio

  19. True Wealth - Financial and Investing Podcast ·

    Could Wall Street Get WILD?

    Unidentified speaker (speaker_1) neutral

    “like, do you want the boring Johnson and Johnson like Procter and Gamble style companies or do you want NVIDIA? I'll take the boring stuff over the next six months. Or the”

    Listen at 40:05Original audio

  20. In the Money with Amber Kanwar ·

    The Midterms, the Markets and a Surprising Opportunity in Healthcare

    Unidentified speaker neutral

    “And so um, you know, wonderful new technology, but Medtronic and Johnson Johnson are coming in.”

    Listen at 39:47Original audio

  21. In the Money with Amber Kanwar ·

    The Midterms, the Markets and a Surprising Opportunity in Healthcare

    Unidentified speaker neutral

    “I'm going to get these from Johnson and Johnson, or you know, I'm going to get them from uh from somebody else.”

    Listen at 43:51Original audio

  22. Mad Money w/ Jim Cramer ·

    Mad Money w/ Jim Cramer 11/2/26

    Unidentified speaker (speaker_1) bullish

    “Hey uh my family and I have both worked and invested in Johnson Johnson for about 30 years and always been happy with the company.”

    Listen at 41:18Original audio

  23. Mad Money w/ Jim Cramer ·

    Mad Money w/ Jim Cramer 11/2/26

    Unidentified speaker (speaker_3) neutral

    “as well as the long awaited closing of Kimberly Clark's acquisition of Kenview, the former consumer health business of Johnson Johnson.”

    Listen at 45:01Original audio

  24. The Morning Filter ·

    3 Stocks to Sell and 3 Stocks to Buy for November

    Unidentified speaker bearish

    “Um, number three, we have Johnson and Johnson. Now, this is one of those core holding stocks that we just talked about. Uh, tell us why it's on your sell list. Exactly. And I think this is one that we talked about as being a core holding. And our first recommendation on JJ was all the way back in March 18th of 2024. And so while I still think you might want to hold some of this position, I think you also need to think about taking some of the profit off the table, freeing up some of that dry powder so that way if the stock does fall, you have the ability to dollar cost average in, you know, to the downside, or maybe even just, you know, reinvest in some other stocks that are trading at a better, you know, margin of safety from their long-term intrinsic valuation. This is one of these stocks I think it's been able to benefit from the you know anything but AI trade. And I think, you know, we're looking at pretty conservative forecasts. Our five-year compound annual growth rate from revenue is six and a half percent. You know, we're looking for operating margin expansion to 31.3% from 26.4%. You know, that might be a little on the high side. I mean, it's averaged 26%, you know, over the past five years. Yeah, we're looking at five-year compound annual growth rate for earnings of 8.1%. But it's just that as much as the stock has traded up, it's now trading at 24 times 2026 earnings estimates. Even on a forward multiple using our earnings estimate for 2027, it's still a 22 times multiple, which in my mind is probably just too high for an 8% earnings growth.”

    Listen at 36:21Original audio

  25. The Money Signal: From Main Street to Wall Street ·

    How Brands Track Your Data to Predict What You’ll Buy Next

    Unidentified speaker (speaker_1) neutral

    “K View is the new spin-off of Johnson and Johnson. They do Listerine and a number of other products.”

    Listen at 42:59Original audio

  26. WEALTHTRACK ·

    Lessons From Investment Greats’ Responses to the Market Chaos of 2008 (Classic)

    Unidentified speaker neutral

    “And so uh and and uh uh uh there's such an attractive uh uh array of options out there, and I've I've given a list of 10 or so, but they include stocks like UPS, uh DuPont 3M, Johnson ⁇ Johnson is over 3% yield now, BP Amico, uh uh Kimberly Clark, some of the great names in uh in this country, and so I think that's a uh a a good package of things for people to uh to think about.”

    Listen at 27:28Original audio

  27. Stock Market Today With IBD ·

    Watch These Levels As Indexes Plunge; eBay, Regeneron, CBOE In Focus

    Unidentified speaker neutral

    “Or let's go to a Johnson and Johnson.”

    Listen at 26:48Original audio

  28. Stock Market Today With IBD ·

    Watch These Levels As Indexes Plunge; eBay, Regeneron, CBOE In Focus

    Unidentified speaker neutral

    “Those people aren't trading Johnson and Johnson and Coke and Procter and Gamble.”

    Listen at 28:51Original audio

Claims about this asset

  • Unidentified speaker (UNKNOWN) says: Kenvue is a spin-off of Johnson & Johnson that produces Listerine.

    How to verify: Check Kenvue's corporate history and product portfolio on the SEC EDGAR database or Kenvue's investor relations page. For recent events, verify 2026-08-02 through 2026-11-02. Use another period only when the speaker explicitly names it.

    How Brands Track Your Data to Predict What You’ll Buy NextPrimary source
  • Unidentified speaker (speaker_3) says: Johnson & Johnson is getting rid of its commodity-based synthetic joint business.

    How to verify: Check Johnson & Johnson (JNJ) investor presentations or press releases regarding the divestiture of its orthopedics or synthetic joint assets. For recent events, verify 2026-08-03 through 2026-11-03. Use another period only when the speaker explicitly names it.

    Mad Money w/ Jim Cramer 11/2/26Primary source
  • Unidentified speaker (speaker_1) says: Johnson & Johnson is one of two U.S. companies that still have a AAA credit rating.

    How to verify: Check current credit ratings from major agencies (S&P, Moody's, Fitch) for US corporations to identify those with AAA ratings. For recent events, verify 2026-08-07 through 2026-11-07. Use another period only when the speaker explicitly names it.

    "Your Financial Future" with Nick Colarossi of NJC Investments 11/07/2026Primary source
  • Unidentified speaker (UNKNOWN) says: Alex Gorsky served as chairman and CEO of Johnson & Johnson.

    How to verify: Check Johnson & Johnson investor relations history or SEC proxy statements for leadership tenure dates. For recent events, verify 2026-08-08 through 2026-11-08. Use another period only when the speaker explicitly names it.

    Rebuilding resilience in America’s pharmaceutical supply chainPrimary source
  • Unidentified speaker (speaker_1) says: Adam Walker worked for Johnson & Johnson and its spin-off Kenvue, leading brands like Listerine, Neutrogena, and React.

    How to verify: Adam Walker's LinkedIn profile or corporate press releases from Johnson & Johnson/Kenvue regarding brand leadership. For recent events, verify 2026-08-10 through 2026-11-10. Use another period only when the speaker explicitly names it.

    Expert Advice Series | Episode 381: Why The Best Business Owners Have a Coach? with Adam WalkerPrimary source
  • Bill Gunderson says: NVIDIA is trading at 11 times forward earnings, while Johnson & Johnson is trading at 25 times forward earnings.

    How to verify: Check financial data providers (e.g., Yahoo Finance, Bloomberg) for NVIDIA (NVDA) and Johnson & Johnson (JNJ) forward P/E ratios as of November 11, 2026. For recent events, verify 2026-08-11 through 2026-11-11. Use another period only when the speaker explicitly names it.

    Wednesday Nov. 11, 2016 - Bill's Comment on NVDA in Barrons. Huge Jump in AI stocks today.Primary source
  • Unidentified speaker (speaker_1) says: Johnson & Johnson trades at a forward PE of 24.

    How to verify: Current JNJ stock price divided by forward 12-month earnings estimates. For recent events, verify 2026-08-12 through 2026-11-12. Use another period only when the speaker explicitly names it.

    Thursday Nov. 12, 2026Primary source
  • Unidentified speaker (speaker_3) says: Johnson & Johnson and 3M have increased their dividends every year for 50 years.

    How to verify: Company investor relations pages or dividend history databases (e.g., S&P Dividend Aristocrats list, Yahoo Finance) to confirm 50+ consecutive years of dividend increases. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

    Great Investor Hersh Cohen explains his powerful compounding strategy.Primary source
  • Unidentified speaker (speaker_2) says: Portfolio managers are selling Intel and NVIDIA to buy Procter & Gamble and Johnson & Johnson.

    How to verify: Check institutional ownership reports (13F filings) or fund flow data for the specified period to see if there was a net rotation from semiconductors to consumer staples. For recent events, verify 2026-08-13 through 2026-11-13. Use another period only when the speaker explicitly names it.

    Worsening [11.13.2026]Primary source
  • Unidentified speaker (UNKNOWN) says: Johnson & Johnson (JNJ) has a beta of 0.21, a dividend yield of 1.9%, and is up 38% year-to-date.

    How to verify: Check Yahoo Finance or Bloomberg for JNJ's beta, dividend yield, and YTD price change as of November 2026. For recent events, verify 2026-08-14 through 2026-11-14. Use another period only when the speaker explicitly names it.

    "Your Financial Future" with Nick Colarossi of NJC Investments 11/14/2026Primary source

Often mentioned with

Podcasts that cover it most

  1. Investor's Edge with Gary Kaltbaum · 5 mentions
  2. Mad Money w/ Jim Cramer · 3 mentions
  3. WEALTHTRACK · 2 mentions
  4. Best Stocks Now with Bill Gunderson · 2 mentions
  5. In the Money with Amber Kanwar · 2 mentions
  6. Stock Market Today With IBD · 2 mentions
  7. Brew Markets · 1 mentions
  8. Felix Nikolas Prehn's Podcast · 1 mentions
  9. Daily Stock Picks · 1 mentions
  10. Morning Call · 1 mentions
  11. " Your Financial Future" with Nick Colarossi · 1 mentions
  12. CNBC's "Fast Money" · 1 mentions
  13. The Simply Investing Dividend Podcast · 1 mentions
  14. Making Sense · 1 mentions
  15. Ticker Take · 1 mentions
  16. True Wealth - Financial and Investing Podcast · 1 mentions
  17. The Morning Filter · 1 mentions
  18. The Money Signal: From Main Street to Wall Street · 1 mentions